Under one in 10 patients eligible to benefit from weight-loss injections like Wegovy can access them, warns the WHO as it publishes its first guidance on the therapies.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is urging increased and just availability to these injectable treatments.
According to projections, more than two billion are projected to be living with obesity by 2030 unless action is taken.
"Our latest guidelines acknowledges that obesity is a long-term condition that can be managed with holistic and lifelong treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, constrained manufacturing, and distribution challenges are major obstacles to universal access to the treatments that can assist patients in reducing substantial body mass, explains the body.
Skinny Jab Scarcity
Despite the present best projected case, the supply of such drugs could only cover about 100 million people – less than 10% of the global need, according to the WHO.
The advice calls on countries and companies to expand access, by strategies like licensing agreements.
A patent on semaglutide – the main component of a leading brand – is due to expire in a number of countries in 2026.
The Way Obesity Drugs Work
These medications mimick a biological compound to slow digestion, reduce hunger and enhance feelings of fullness so individuals reduce food intake.
Individuals usually begin shedding pounds within a few weeks of beginning the regular doses.
Studies suggests patients may regain a significant portion a year later of stopping the treatment, when their normal appetite resume.
To be above a healthy weight increases your likelihood for contracting medical conditions, such as type 2 diabetes, heart disease, brain attack, and specific cancers.
Excess weight affects individuals in all nations and was linked to millions of deaths worldwide in 2024, per the health agency.
